Clinical Trials · NCT05322200
The POST-ACS Study
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Swansea Bay University Health Board
- Enrollment
- 140
- Start date
- Aug 2022
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated "Plaque Maps" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.